One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Atopic Dermatitis

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Br J Dermatol

Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C, UK-Irish A-STAR Study Group

doi: 10.1093/bjd/ljae287

Atopic Dermatitis

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

J Am Acad Dermatol

Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA

doi: 10.1016/j.jaad.2024.04.026

Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

J Allergy Clin Immunol Pract

Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T, FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group

doi: 10.1016/j.jaip.2024.12.001

Atopic Dermatitis

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

JAMA Dermatol

Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E, Dubost-Brama A, Shabbir A

doi: 10.1001/jamadermatol.2024.1536

Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

J Am Acad Dermatol

Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR

doi: 10.1016/j.jaad.2024.09.039

Rheumatoid Arthritis

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Rheumatol Ther

Taylor PC, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B, Alten R, Nash P, Feist E

doi: 10.1007/s40744-024-00732-8

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Atopic Dermatitis

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Acta Derm Venereol

Calabrese L, Cinotti E, D'Onghia M, Cartocci A, Rubegni P, Maccari F, Boulard C, Reguiai Z, Becherel PA, Jacobzone C, Begon E, Fite C, Walls B, Liegeon AL, Parier J, Chaby G, Perrot JL, Omcci Group

doi: 10.2340/actadv.v105.42275

Related content

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study